Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
| Revenue (TTM) | $8.51B |
| Gross Profit (TTM) | $5.95B |
| EBITDA | $2.56B |
| Operating Margin | 18.00% |
| Return on Equity | 6.41% |
| Return on Assets | 3.96% |
| Revenue/Share (TTM) | $43.50 |
| Book Value | $66.23 |
| Price-to-Book | 1.52 |
| Price-to-Sales (TTM) | 2.26 |
| EV/Revenue | 3.087 |
| EV/EBITDA | 11.27 |
| Quarterly Earnings Growth (YoY) | 33.80% |
| Quarterly Revenue Growth (YoY) | 4.80% |
| Shares Outstanding | $190.74M |
| Float | $190.20M |
| % Insiders | 0.16% |
| % Institutions | 111.43% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript
ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.07 per share a year ago.
Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per share were $1.03, an increase of 33.8%; adjusted1 diluted earnings per share were $2.07, consistent with the prior year period Company updates full-year 2026 financial guidance WARSAW, Ind., Aug. 5, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and (SIX: ZBH) today reported financial results for the quarter ended June 30, 2026.
Can Zimmer Biomet, Charles River Laboratories and Bio-Techne meet earnings expectations? See the MedTech trends and company-specific drivers in focus.
ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZBH and any ticker you trade — then tracks every position and per-strategy win rate.
